These PDx anitbodies likely have a range of epitopes, affinities, Fc functions, glycosylations, etc.–all of which could affect activity, but differential activity isn’t likely predictable from preclinical work. And in the real-world setting many of the nuanced differences may disappear in the face of disease complexity.
Will Anti-CD47 crash the party?
http://www.forbes.com/sites/brucebooth/2016/06/22/immuno-oncology-the-strategic-supernova-in-cancer-today/#59576c8e1d44
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
